

## BioNTech Reports Strong H1 2024 with Key Advances in COVID-19 Vaccines, Oncology Pipeline, and Strategic Partnerships

02 September 2024 | Analysis

**BioNTech Secures Positive EU Opinion on Omicron JN.1-Adapted Vaccine, Expands Oncology Portfolio with FDA Fast Track Designation, and Strengthens Global Vaccine Ecosystem through Strategic Collaborations**



BioNTech SE (Nasdaq: BNTX), a global leader in immunotherapy and innovative vaccine development, has reported significant advancements across multiple domains during the first half of 2024. The company's efforts were marked by key developments in its COVID-19 vaccine program, oncology pipeline, and strategic partnerships, underscoring its commitment to addressing global health challenges.

### **COVID-19 Vaccine Progress**

In its ongoing fight against COVID-19, BioNTech, in collaboration with Pfizer, achieved a major milestone with the European Union's Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion on an Omicron JN.1-adapted COVID-19 vaccine. This vaccine is designed to enhance immune responses against the JN.1 sublineages and is anticipated to receive approval for distribution across EU member states. Concurrently, BioNTech expects the U.S. FDA to grant approval, furthering its mission to adapt and evolve its vaccine offerings in response to emerging variants.

### **Oncology Pipeline Expansion**

BioNTech's oncology pipeline has also witnessed substantial progress. In partnership with DualityBio, the company received FDA Fast Track Designation for BNT324/DB-1311, an antibody-drug conjugate (ADC) targeting prostate cancer. This marks the third ADC candidate from their collaboration to receive this designation, highlighting the potential of BioNTech's oncology pipeline. Additionally, BioNTech presented promising clinical trial data at the American Society of Clinical Oncology (ASCO) Annual Meeting, reinforcing its goal to launch its first cancer immunotherapy by 2026 and to secure approvals for ten cancer indications by 2030.

### **Strategic Partnerships and Global Impact**

Strategic partnerships continue to be a cornerstone of BioNTech's growth. The company expanded its collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to bolster the mRNA vaccine ecosystem in Africa. This partnership aims to enhance BioNTech's manufacturing capabilities in Kigali, Rwanda, with a focus on establishing a sustainable vaccine ecosystem and improving vaccine accessibility across the continent.

### **Financial and Leadership Updates**

Despite reporting a net loss of €315.1 million in Q1 2024, BioNTech remains financially strong, with revenues of €187.6 million and a solid cash position of €16.9 billion. The company is poised to accelerate its oncology pipeline, with plans to initiate multiple registrational trials by the end of 2024.

In terms of leadership, BioNTech appointed Annemarie Hanekamp as the new Chief Commercial Officer, effective July 1, 2024. She succeeds Sean Marett, who will transition into a specialist advisory role, bringing his vast experience to support BioNTech's continued growth.

### **Sustainability Initiatives**

BioNTech has also advanced its environmental sustainability efforts, with its emissions reduction targets receiving validation from the Science Based Targets initiative (SBTi). This aligns with global climate goals and demonstrates BioNTech's commitment to reducing its environmental impact.

BioNTech's activities from January to June 2024 reflect a robust and strategic approach to advancing its infectious disease and oncology programs, while also fostering global partnerships, sustainability, and leadership development. These efforts position the company for continued growth and success in addressing some of the world's most pressing health challenges.